Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 134 articles:
HTML format

Single Articles

    January 2024

  1. Retraction: Potent Anti-Proliferative, Pro-Apoptotic Activity of the Maytenus Royleanus Extract against Prostate Cancer Cells: Evidence in In-Vitro and In-Vivo Models.
    PLoS One. 2024;19:e0297383.

  2. WESTERBERG M, Irenaeus S, Garmo H, Stattin P, et al
    Development and validation of a multi-dimensional diagnosis-based comorbidity index that improves prediction of death in men with prostate cancer: Nationwide, population-based register study.
    PLoS One. 2024;19:e0296804.
    PubMed     Abstract available

  3. WU H, Wu Y, He P, Liang J, et al
    A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.
    PLoS One. 2024;19:e0285745.
    PubMed     Abstract available

  4. JONEUS P, Johansson P, Langenskiold S
    Novel hormonal therapy versus standard of care-A registry-based comparative effectiveness evaluation for mCRPC-patients.
    PLoS One. 2024;19:e0290833.
    PubMed     Abstract available

  5. NORIEGA LANDA E, Quaye GE, Su X, Badmos S, et al
    Urinary fatty acid biomarkers for prostate cancer detection.
    PLoS One. 2024;19:e0297615.
    PubMed     Abstract available

  6. ZAFEIROPOULOU K, Kalampounias G, Alexis S, Anastasopoulos D, et al
    Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.
    PLoS One. 2024;19:e0289904.
    PubMed     Abstract available

  7. Retraction: Somatostatin Derivative (smsDX) Targets Cellular Metabolism in Prostate Cancer Cells after Androgen Deprivation Therapy.
    PLoS One. 2024;19:e0299822.

    January 2023
  8. CHEN WC, Li JR, Wang SS, Chen CS, et al
    Conventional androgen deprivation therapy is associated with an increased risk of fracture in advanced prostate cancer, a nationwide population-based study.
    PLoS One. 2023;18:e0279981.
    PubMed     Abstract available

  9. RAKAUSKAS A, Peters M, Martel P, van Rossum PSN, et al
    Do cancer detection rates differ between transperineal and transrectal micro-ultrasound mpMRI-fusion-targeted prostate biopsies? A propensity score-matched study.
    PLoS One. 2023;18:e0280262.
    PubMed     Abstract available

  10. HAN JH, Chung DH, Cho MC, Ku JH, et al
    Natural history of incidentally diagnosed prostate cancer after holmium laser enucleation of the prostate.
    PLoS One. 2023;18:e0278931.
    PubMed     Abstract available

  11. BRAGA-BASARIA M, Travison TG, Taplin ME, Lin A, et al
    Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study.
    PLoS One. 2023;18:e0281508.
    PubMed     Abstract available

  12. NATKIN R, Pennanen P, Syvala H, Blauer M, et al
    Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.
    PLoS One. 2023;18:e0281645.
    PubMed     Abstract available

  13. CHEN WH, Lee YK, Kuo HC, Wang JH, et al
    Oncological and functional outcomes of high-risk and very high-risk prostate cancer patients after robot-assisted radical prostatectomy.
    PLoS One. 2023;18:e0282494.
    PubMed     Abstract available

  14. HASANNEJADASL H, Roumen C, van der Poel H, Vanneste B, et al
    Development and external validation of multivariate prediction models for erectile dysfunction in men with localized prostate cancer.
    PLoS One. 2023;18:e0276815.
    PubMed     Abstract available

  15. DERIS A, Sohrabi-Haghighat M
    Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
    PLoS One. 2023;18:e0282646.
    PubMed     Abstract available

  16. DUENWEG SR, Brehler M, Bobholz SA, Lowman AK, et al
    Comparison of a machine and deep learning model for automated tumor annotation on digitized whole slide prostate cancer histology.
    PLoS One. 2023;18:e0278084.
    PubMed     Abstract available

  17. TSAI TH, Chu TW, Lin TH, Hsieh TF, et al
    Ethnic differences in the age-related distribution of serum prostate-specific antigen values: A study in a Taiwanese male population.
    PLoS One. 2023;18:e0283040.
    PubMed     Abstract available

  18. LAWRENCE EM, Kieler M, Cooley G, Wells SA, et al
    Assessment of 18F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability.
    PLoS One. 2023;18:e0283830.
    PubMed     Abstract available

  19. BATES-FRASER LC, Riley S, Stopforth C, Moertl K, et al
    Home-based exercise improves quality of life in breast and prostate cancer survivors: A meta-analysis.
    PLoS One. 2023;18:e0284427.
    PubMed     Abstract available

  20. BRUNCKHORST O, Liszka J, James C, Fanshawe JB, et al
    Mental wellbeing and quality of life in prostate cancer (MIND-P): Protocol for a multi-institutional prospective cohort study.
    PLoS One. 2023;18:e0284727.
    PubMed     Abstract available

  21. CHINH K, Wu W, Johns SA, Stutz PV, et al
    Development and preliminary validation of the Brief Self-Compassion Inventory.
    PLoS One. 2023;18:e0285658.
    PubMed     Abstract available

  22. PAPADOPOULOS E, Wong AKO, Law SHC, Zhang LZJ, et al
    The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.
    PLoS One. 2023;18:e0286381.
    PubMed     Abstract available

  23. MUMTAZ S, Usman Rashid M, Khan RU, Malkani N, et al
    miR-4482 and miR-3912 aim for 3'UTR of ERG mRNA in prostate cancer.
    PLoS One. 2023;18:e0286996.
    PubMed     Abstract available

  24. HELLSTERN M, Martinez C, Wallenhorst C, Beyersdorff D, et al
    Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue.
    PLoS One. 2023;18:e0287651.
    PubMed     Abstract available

  25. WAN B, Lu L, Lv C
    Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer.
    PLoS One. 2023;18:e0286219.
    PubMed     Abstract available

  26. MOHAMMAD AH, Couture F, Gamache I, Chen O, et al
    Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.
    PLoS One. 2023;18:e0288622.
    PubMed     Abstract available

  27. MOBADERI T, Kazemnejad A, Salehi M
    Bayesian clustering of 109 worldwide countries according to the trend of prostate cancer mortality rates from 1990 to 2019.
    PLoS One. 2023;18:e0290110.
    PubMed     Abstract available

  28. MOHSENI M, Ayatollahi H, Arefpour AM
    Electronic patient-reported outcome (ePRO) application for patients with prostate cancer.
    PLoS One. 2023;18:e0289974.
    PubMed     Abstract available

  29. NYATI S, Stricker H, Barton KN, Li P, et al
    A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent localized prostate adenocarcinoma.
    PLoS One. 2023;18:e0291315.
    PubMed     Abstract available

  30. OKUMURA S, Ohsato Y
    A novel rapid detection method for a single-nucleotide substitution mutation derived from canine urothelial and prostatic carcinoma cells present in small amounts in urine sediments.
    PLoS One. 2023;18:e0286229.
    PubMed     Abstract available

  31. LI J, Gu T, Hu S, Jin B, et al
    Anti-proliferative effect of Cannabidiol in Prostate cancer cell PC3 is mediated by apoptotic cell death, NFkappaB activation, increased oxidative stress, and lower reduced glutathione status.
    PLoS One. 2023;18:e0286758.
    PubMed     Abstract available

  32. HILLOWE A, Gordon C, Wang L, Rizzo RC, et al
    Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
    PLoS One. 2023;18:e0292483.
    PubMed     Abstract available

  33. LYLES RDZ, Martinez MJ, Sherman B, Schurer S, et al
    Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens.
    PLoS One. 2023;18:e0287126.
    PubMed     Abstract available

  34. JOHANSSON P, Joneus P, Langenskiold S
    Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide.
    PLoS One. 2023;18:e0293000.
    PubMed     Abstract available

  35. LUINING WI, Oprea-Lager DE, Vis AN, van Moorselaar RJA, et al
    Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer.
    PLoS One. 2023;18:e0293672.
    PubMed     Abstract available

  36. CAMERON JK, Chandrasiri U, Millar J, Aitken JF, et al
    Disease mapping: Geographic differences in population rates of interventional treatment for prostate cancer in Australia.
    PLoS One. 2023;18:e0293954.
    PubMed     Abstract available

  37. SIBERT NT, Kurth T, Breidenbach C, Wesselmann S, et al
    Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patients.
    PLoS One. 2023;18:e0295179.
    PubMed     Abstract available

  38. KWON SY, Park JM
    The assessment of erectile dysfunction after radical prostatectomy using pudendal somatosensory evoked potential.
    PLoS One. 2023;18:e0292847.
    PubMed     Abstract available

  39. XIAO Z, Xiao P, Wang Y, Fang C, et al
    Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review.
    PLoS One. 2023;18:e0285335.
    PubMed     Abstract available

  40. CHANG HJ, Moi SH, Chan YJ, Lan TY, et al
    A non-socially-sensitive predictive model of prostate cancer for Asian males with benign prostatic hyperplasia: A multi-site cross-sectional case-control study.
    PLoS One. 2023;18:e0295608.
    PubMed     Abstract available

    January 2022
  41. CHAPLOW ZL, Lucas AR, Grainger E, Simpson C, et al
    Social cognitive outcomes are associated with improvements in mobility performance following lifestyle intervention in prostate cancer patients undergoing androgen deprivation therapy.
    PLoS One. 2022;17:e0263136.
    PubMed     Abstract available

  42. NYAMSAMBUU A, Khan MA, Zhou X, Chen HC, et al
    Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion.
    PLoS One. 2022;17:e0261341.
    PubMed     Abstract available

  43. KASIVISVANATHAN V, Chan VW, Clement KD, Levis B, et al
    A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer.
    PLoS One. 2022;17:e0263345.
    PubMed     Abstract available

  44. SHU W, Tao W, Chunyan H, Jie F, et al
    Preoperative nutritional evaluation of prostate cancer patients undergoing laparoscopic radical prostatectomy.
    PLoS One. 2022;17:e0262630.
    PubMed     Abstract available

  45. LARKIN D, Birtle AJ, Bradley L, Dey P, et al
    A systematic review of disease related stigmatization in patients living with prostate cancer.
    PLoS One. 2022;17:e0261557.
    PubMed     Abstract available

  46. ROGGERO CM, Esser V, Duan L, Rice AM, et al
    Poly-glutamine-dependent self-association as a potential mechanism for regulation of androgen receptor activity.
    PLoS One. 2022;17:e0258876.
    PubMed     Abstract available

  47. FORYS U, Nahshony A, Elishmereni M
    Mathematical model of hormone sensitive prostate cancer treatment using leuprolide: A small step towards personalization.
    PLoS One. 2022;17:e0263648.
    PubMed     Abstract available

  48. SHAO W, Zhang H, Qi H, Zhang Y, et al
    The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis.
    PLoS One. 2022;17:e0263918.
    PubMed     Abstract available

  49. ZHANG H, Yang H, Bandyopadhyay S, Milano MT, et al
    Increased risk of high-grade prostate cancer among testicular cancer survivors.
    PLoS One. 2022;17:e0263573.
    PubMed     Abstract available

  50. MARSDEN T, McCartan N, Brown L, Rodriguez-Justo M, et al
    The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.
    PLoS One. 2022;17:e0259672.
    PubMed     Abstract available

  51. SIEWE N, Friedman A
    Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
    PLoS One. 2022;17:e0262453.
    PubMed     Abstract available

  52. Expression of Concern: Akt Mediates Metastasis-Associated Gene 1 (MTA1) Regulating the Expression of E-cadherin and Promoting the Invasiveness of Prostate Cancer Cells.
    PLoS One. 2022;17:e0266930.

  53. LIN SF, Lin HC, Lee MY, Keller JJ, et al
    Association between GnRH analogue use and atopic diseases in patients with prostate cancer: A population-based retrospective cohort study.
    PLoS One. 2022;17:e0266771.
    PubMed     Abstract available

  54. LEE JJB, Lee E, Choi WH, Kim J, et al
    Dosimetric outcomes of preoperative treatment planning with intraoperative optimization using stranded seeds in prostate brachytherapy.
    PLoS One. 2022;17:e0265143.
    PubMed     Abstract available

  55. TZELVES L, Manolitsis I, Varkarakis I, Ivanovic M, et al
    Artificial intelligence supporting cancer patients across Europe-The ASCAPE project.
    PLoS One. 2022;17:e0265127.
    PubMed     Abstract available

  56. LEE ST, Wong PF, He H, Hooper JD, et al
    Correction: Alpha-Tomatine Attenuation of In Vivo Growth of Subcutaneous and Orthotopic Xenograft Tumors of Human Prostate Carcinoma PC-3 Cells Is Accompanied by Inactivation of Nuclear Factor-Kappa B Signaling.
    PLoS One. 2022;17:e0268234.
    PubMed     Abstract available

  57. WIAFE E, Mensah KB, Oosthuizen F, Bangalee V, et al
    A pilot study of the knowledge, awareness and perception of prostate cancer in Ghanaian women.
    PLoS One. 2022;17:e0267797.
    PubMed     Abstract available

  58. LIN Z, Zhang Z, Ye X, Zhu M, et al
    Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer.
    PLoS One. 2022;17:e0263291.
    PubMed     Abstract available

  59. Retraction: Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.
    PLoS One. 2022;17:e0268981.

  60. CLARKE CS, Hunter RM, Gabrio A, Brawley CD, et al
    Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
    PLoS One. 2022;17:e0269192.
    PubMed     Abstract available

  61. CHUNG DY, Jung HD, Kim DK, Lee MH, et al
    Outcomes of Retzius-sparing versus conventional robot-assisted radical prostatectomy: A KSER update series systematic review and meta-analysis.
    PLoS One. 2022;17:e0268182.
    PubMed     Abstract available

  62. MOKOATLE M, Mapiye D, Marivate V, Hayes VM, et al
    Discriminatory Gleason grade group signatures of prostate cancer: An application of machine learning methods.
    PLoS One. 2022;17:e0267714.
    PubMed     Abstract available

  63. HARKE NN, Wagner C, Hermann RM, Hadaschik BA, et al
    Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
    PLoS One. 2022;17:e0269827.
    PubMed     Abstract available

  64. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2022;17:e0270734.
    PubMed     Abstract available

  65. LI JR, Wang SS, Chen CS, Cheng CL, et al
    Conventional androgen deprivation therapy is associated with an increased risk of cardiovascular disease in advanced prostate cancer, a nationwide population-based study.
    PLoS One. 2022;17:e0270292.
    PubMed     Abstract available

  66. WANG BJ, Huang SH, Kao CL, Muller CJF, et al
    Aspalathus linearis suppresses cell survival and proliferation of enzalutamide-resistant prostate cancer cells via inhibition of c-Myc and stability of androgen receptor.
    PLoS One. 2022;17:e0270803.
    PubMed     Abstract available

  67. SHAHAIT M, Abu-Hijlih R, Salamat A, Abou Heidar N, et al
    Bone marrow involvement in patients with metastatic castration sensitive prostate cancer.
    PLoS One. 2022;17:e0270956.
    PubMed     Abstract available

  68. ALBERTS I, Butikofer L, Rominger A, Afshar-Oromieh A, et al
    A randomised, prospective and head-to-head comparison of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 for the detection of recurrent prostate cancer in PSMA-ligand PET/CT-Protocol design and rationale.
    PLoS One. 2022;17:e0270269.
    PubMed     Abstract available

  69. HENKEL M, Horn T, Leboutte F, Trotsenko P, et al
    Initial experience with AI Pathway Companion: Evaluation of dashboard-enhanced clinical decision making in prostate cancer screening.
    PLoS One. 2022;17:e0271183.
    PubMed     Abstract available

  70. OWOO B, Ninnoni JPK, Ampofo EA, Seidu AA, et al
    "I always find myself very tired and exhausted": The physical impact of caring; a descriptive phenomenological study of the experiences of prostate cancer caregivers in Cape Coast, Ghana.
    PLoS One. 2022;17:e0268627.
    PubMed     Abstract available

  71. KATZENDORN O, von Klot CAJ, Mahjoub S, Faraj Tabrizi P, et al
    Combination of PI-RADS score and mRNA urine test-A novel scoring system for improved detection of prostate cancer.
    PLoS One. 2022;17:e0271981.
    PubMed     Abstract available

  72. GUIN S, Liaw BK, Jun T, Ayers K, et al
    Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.
    PLoS One. 2022;17:e0264800.
    PubMed     Abstract available

  73. BAKER A, Khalid M, Uddin I, Khan MS, et al
    Targeted non AR mediated smart delivery of abiraterone to the prostate cancer.
    PLoS One. 2022;17:e0272396.
    PubMed     Abstract available

  74. HELFAND BT, Paterakos M, Wang CH, Talaty P, et al
    The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer.
    PLoS One. 2022;17:e0273782.
    PubMed     Abstract available

  75. SHAH YB, Shaver AL, Kelly WK, Lu-Yao G, et al
    A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer.
    PLoS One. 2022;17:e0273826.
    PubMed     Abstract available

  76. PANTELIDOU M, Caglic I, George A, Blyuss O, et al
    Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study.
    PLoS One. 2022;17:e0274014.
    PubMed     Abstract available

  77. BLOEMBERG J, Trauzettel F, Coolen B, Dodou D, et al
    Design and evaluation of an MRI-ready, self-propelled needle for prostate interventions.
    PLoS One. 2022;17:e0274063.
    PubMed     Abstract available

  78. CHEN C, Lin M, Yu D, Qin W, et al
    Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials.
    PLoS One. 2022;17:e0275176.
    PubMed     Abstract available

  79. TAKESHIMA Y, Yamada Y, Takemura K, Kimura N, et al
    The association between the parameters of uroflowmetry and lower urinary tract symptoms in prostate cancer patients after robot-assisted radical prostatectomy.
    PLoS One. 2022;17:e0275069.
    PubMed     Abstract available

  80. JAGARLAMUDI KK, L S, M Z, J O, et al
    Analytical and clinical characterization of an optimized dual monoclonal sandwich ELISA for the quantification of thymidine kinase 1 (TK1) protein in human blood samples.
    PLoS One. 2022;17:e0275444.
    PubMed     Abstract available

  81. KANAO K, Takahashi T, Umezawa Y, Okabe T, et al
    Efficacy of abiraterone acetate for high-risk hormone-naive metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
    PLoS One. 2022;17:e0276081.
    PubMed     Abstract available

  82. MAPANGA W, Norris SA, Craig A, Pumpalova Y, et al
    Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa.
    PLoS One. 2022;17:e0276050.
    PubMed     Abstract available

  83. RISE K, Tessem MB, Drablos F, Rye MB, et al
    FunHoP analysis reveals upregulation of mitochondrial genes in prostate cancer.
    PLoS One. 2022;17:e0275621.
    PubMed     Abstract available

  84. MEURMAN JH, Kallmen H, Andersson LC, Yucel-Lindberg T, et al
    Prevalence of cancer in relation to signs of periodontal inflammation.
    PLoS One. 2022;17:e0276375.
    PubMed     Abstract available

  85. BARBIER MC, Tomonaga Y, Menges D, Yebyo HG, et al
    Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
    PLoS One. 2022;17:e0277282.
    PubMed     Abstract available

  86. VILJOEN B, Hofman MS, Chambers SK, Dunn J, et al
    Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study.
    PLoS One. 2022;17:e0276063.
    PubMed     Abstract available

  87. MYERS MS, Kosmacek EA, Chatterjee A, E Oberley-Deegan R, et al
    CT vs. bioluminescence: A comparison of imaging techniques for orthotopic prostate tumors in mice.
    PLoS One. 2022;17:e0277239.
    PubMed     Abstract available

  88. MENA E, Shih J, Chung JY, Jones J, et al
    Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0277407.
    PubMed     Abstract available

  89. ORRASON AW, Westerberg M, Albertsen P, Styrke J, et al
    Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy.
    PLoS One. 2022;17:e0277784.
    PubMed     Abstract available

  90. PRATT NL, Cicuttini FM, Wang Y, Graves SE, et al
    No increased risk of cancer associated with metal-on-metal or ceramic-on-ceramic procedures compared to other bearing surfaces in patients with total hip arthroplasty: A nationwide linked registry cohort analysis of 167,837 patients.
    PLoS One. 2022;17:e0278241.
    PubMed     Abstract available

  91. KARKEET RM, Zekri AN, Sayed-Ahmed MM, Sherif GM, et al
    The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
    PLoS One. 2022;17:e0278282.
    PubMed     Abstract available

  92. HART JE, Mohan S, Davies KG, Ferneyhough B, et al
    Hexapeptides from mammalian inhibitory hormone hunt activate and inactivate nematode reproduction.
    PLoS One. 2022;17:e0278049.
    PubMed     Abstract available

  93. VYAS N, Brunckhorst O, Fox L, Van Hemelrijck M, et al
    Undergoing radical treatment for prostate cancer and its impact on wellbeing: A qualitative study exploring men's experiences.
    PLoS One. 2022;17:e0279250.
    PubMed     Abstract available

  94. DING H, He C, Tong Y, Fang Q, et al
    Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    PLoS One. 2022;17:e0279286.
    PubMed     Abstract available

    January 2021
  95. ZIAYEE F, Ullrich T, Blondin D, Irmer H, et al
    Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    PLoS One. 2021;16:e0249532.
    PubMed     Abstract available

  96. KHAIRNAR R, Pugh SL, Sandler HM, Lee WR, et al
    Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    PLoS One. 2021;16:e0249123.
    PubMed     Abstract available

  97. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed     Abstract available

  98. ZHANG P, Tan X, Zhang D, Gong Q, et al
    Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
    PLoS One. 2021;16:e0249951.
    PubMed     Abstract available

  99. YADAV MP, Ballal S, Sahoo RK, Tripathi M, et al
    Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    PLoS One. 2021;16:e0251375.
    PubMed     Abstract available

  100. SAIDOVA AA, Potashnikova DM, Tvorogova AV, Paklina OV, et al
    Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
    PLoS One. 2021;16:e0251961.
    PubMed     Abstract available

  101. Retraction: Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer.
    PLoS One. 2021;16:e0253350.

  102. LOUGHNEY L, McGowan R, O'Malley K, McCaffrey N, et al
    Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study.
    PLoS One. 2021;16:e0253018.
    PubMed     Abstract available

  103. PAROL-KULCZYK M, Gzil A, Maciejewska J, Bodnar M, et al
    Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.
    PLoS One. 2021;16:e0253112.
    PubMed     Abstract available

  104. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0253021.
    PubMed     Abstract available

  105. GUERRIERO I, Ramberg H, Sagini K, Ramirez-Garrastacho M, et al
    Implication of beta2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells.
    PLoS One. 2021;16:e0253828.
    PubMed     Abstract available

  106. JIANG X, Renkema H, Smeitink J, Beyrath J, et al
    Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
    PLoS One. 2021;16:e0254315.
    PubMed     Abstract available

  107. SALMI F, Maachi F, Tazzite A, Aboutaib R, et al
    Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
    PLoS One. 2021;16:e0254101.
    PubMed     Abstract available

  108. RUNDLE AG, Sadasivan SM, Chitale DA, Gupta NS, et al
    Racial differences in the systemic inflammatory response to prostate cancer.
    PLoS One. 2021;16:e0252951.
    PubMed     Abstract available

  109. ZHANG H, Doucette C, Yang H, Bandyopadhyay S, et al
    Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.
    PLoS One. 2021;16:e0253936.
    PubMed     Abstract available

  110. BARRY DELONGCHAMPS N, Schull A, Anract J, Abecassis JP, et al
    Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
    PLoS One. 2021;16:e0252040.
    PubMed     Abstract available

  111. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available

  112. FALLARA G, Gedeborg R, Bill-Axelson A, Garmo H, et al
    A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
    PLoS One. 2021;16:e0255239.
    PubMed     Abstract available

  113. CHO D, Milbury K, Liao Y, Pettaway CA, et al
    Study protocol: One plus one can be greater than two-Ecological momentary assessment for Black prostate cancer survivors and partners.
    PLoS One. 2021;16:e0255614.
    PubMed     Abstract available

  114. WEINER F, Schille JT, Hein JI, Wu XF, et al
    Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.
    PLoS One. 2021;16:e0256468.
    PubMed     Abstract available

  115. PARK J, Park J, Oh S, Yea JW, et al
    Multi-criteria optimization for planning volumetric-modulated arc therapy for prostate cancer.
    PLoS One. 2021;16:e0257216.
    PubMed     Abstract available

  116. KIM D, Kim DY, Kim JS, Hong SK, et al
    Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy.
    PLoS One. 2021;16:e0256778.
    PubMed     Abstract available

  117. CIMORELLI M, Nieuwland R, Varga Z, van der Pol E, et al
    Standardized procedure to measure the size distribution of extracellular vesicles together with other particles in biofluids with microfluidic resistive pulse sensing.
    PLoS One. 2021;16:e0249603.
    PubMed     Abstract available

  118. TSUZUKI S, Nakanishi S, Tamaki M, Oshiro T, et al
    Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
    PLoS One. 2021;16:e0258160.
    PubMed     Abstract available

  119. MINAMITANI M, Mukai T, Yamashita H, Katano A, et al
    Effects on annual income changes after radical radiotherapy versus after prostatectomy in patients with localized prostate cancer with a specific employment status: A web-based pilot study.
    PLoS One. 2021;16:e0258116.
    PubMed     Abstract available

  120. HASHIMOTO Y, Shiina M, Maekawa S, Kato T, et al
    Suppressor effect of catechol-O-methyltransferase gene in prostate cancer.
    PLoS One. 2021;16:e0253877.
    PubMed     Abstract available

  121. VETRICHELVAN O, Gorjala P, Goodman O Jr, Mitra R, et al
    Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis.
    PLoS One. 2021;16:e0257984.
    PubMed     Abstract available

  122. KOGA F, Ito M, Kataoka M, Fukushima H, et al
    Novel anatomical apical dissection utilizing puboprostatic "open-collar" technique: Impact on apical surgical margin and early continence recovery.
    PLoS One. 2021;16:e0249991.
    PubMed     Abstract available

  123. GEDEBORG R, Styrke J, Loeb S, Garmo H, et al
    Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
    PLoS One. 2021;16:e0255966.
    PubMed     Abstract available

  124. CHUNG JH, Jeong JY, Lee JY, Song W, et al
    Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
    PLoS One. 2021;16:e0249709.
    PubMed     Abstract available

  125. MARKERT L, Holdmann J, Klinger C, Kaufmann M, et al
    Small RNAs as biomarkers to differentiate benign and malign prostate diseases: An alternative for transrectal punch biopsy of the prostate?
    PLoS One. 2021;16:e0247930.
    PubMed     Abstract available

  126. ATHANASIOU A, Tennstedt P, Wittig A, Huber R, et al
    A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
    PLoS One. 2021;16:e0259093.
    PubMed     Abstract available

  127. GODTMAN RA, Persson E, Cazzaniga W, Sandin F, et al
    Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study.
    PLoS One. 2021;16:e0253081.
    PubMed     Abstract available

  128. CHOI W, Lee H
    Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
    PLoS One. 2021;16:e0258626.
    PubMed     Abstract available

  129. LUO L, Zhang LL, Tao W, Xia TL, et al
    Prediction of potential prognostic biomarkers in metastatic prostate cancer based on a circular RNA-mediated competing endogenous RNA regulatory network.
    PLoS One. 2021;16:e0260983.
    PubMed     Abstract available

  130. KLOSE K, Packeiser EM, Muller P, Granados-Soler JL, et al
    Metformin and sodium dichloroacetate effects on proliferation, apoptosis, and metabolic activity tested alone and in combination in a canine prostate and a bladder cancer cell line.
    PLoS One. 2021;16:e0257403.
    PubMed     Abstract available

  131. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0262326.
    PubMed     Abstract available

  132. KIM J, Cho S, Park Y, Lee J, et al
    Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.
    PLoS One. 2021;16:e0262017.
    PubMed     Abstract available

  133. VIDAL I, Zheng Q, Hicks JL, Chen J, et al
    GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.
    PLoS One. 2021;16:e0241934.
    PubMed     Abstract available

  134. SYVERSEN IF, Elschot M, Sandsmark E, Bertilsson H, et al
    Exploring the diagnostic potential of adding T2 dependence in diffusion-weighted MR imaging of the prostate.
    PLoS One. 2021;16:e0252387.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.